

QP Code: 104521

Reg. No:

**M.Ch (Gynaecological Oncology) Degree Regular/Supplementary
Examinations December 2025**

Paper IV – Recent Advances in Gynaecologic Oncology

Time: 3 hrs

Max marks: 100

- *Answer all questions to the point neatly and legibly • Do not leave any blank pages between answers • Indicate the question number correctly for the answer in the margin space*
- *Answer all parts of a single question together • Leave sufficient space between answers*
- *Draw table/diagrams/flow charts wherever necessary*

Essay: (20)

1. Describe how has the role of Poly (ADP-ribose) Polymerase inhibitors (PARPi) in the management of epithelial ovarian cancer evolved during the last decade. What are the recent restrictions recommended by FDA on PARPi treatment for ovarian cancer and why. (8+4+8)

Short essays: (8x10=80)

2. Justify the role of simple hysterectomy for the treatment of cervical cancer with reference to recently published literature and ongoing trials.
3. How does the recent ASCO presentation of TRUST trial preliminary results impact on your decision to undertake surgery for ovarian cancer.
4. What was KEYNOTE-A18 trial. Discuss the role of this trial in the management of patients with newly diagnosed advanced cervical cancer. (3+7)
5. Compare the following trials: GOG0213, DESKTOP3, SOC1.
6. What are the components of the RAINBO trial. Describe the trial design of any one of the components. (4+6)
7. What were the findings in INTERLACE trial. How does the findings affect your current strategy for the management for locally advanced cervical cancer. (6+4)
8. What is RACC trial. Discuss the study design of this trial. How is it expected to impact the current surgical practice for cervical cancer. (2+5+3)
9. What are the objectives of PORTEK-4a trial. What are the initial key findings. (5+5)
